

A PROCESS FOR PRODUCING AN IRON-DEXTRAN COMPOUND, IRON-
5 DEXTRAN COMPOUND PRODUCED ACCORDING TO SAID PROCESS,
PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT
OF IRON-DEFICIENCY AND USE OF SAID COMPOUND FOR THE
PREPARATION OF A PARENTERALLY ADMINISTRABLE
PHARMACEUTICAL COMPOSITION

10

A B S T R A C T

In a process for producing an iron-dextran compound for use in parenteral treatment of iron-deficiency in humans or animals a stable compound of
15 desired relatively low molecular weight is obtained by using first hydrogenation and then oxidation to convert reducing terminal groups on the dextran molecules before reaction with the iron. By varying the ratio of hydrogenated groups to oxygenated groups the average
20 molecular weight of the resulting iron-dextran compound can be varied.